SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, was recognized as an “Outstanding Growth Story in Hong Kong Stocks” at the China Capital Market Development Forum, held in Shanghai from September 16–17 and hosted by ChinaFund. The award highlights Hong Kong-listed companies with exceptional performance in technology innovation, earnings growth and industry influence, and reflects confidence in Fangzhou’s ...

SHANGHAI, Sept. 14, 2025 (GLOBE NEWSWIRE) -- At its 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced the release of its proprietary “XingShi” Large Language Model (“XS LLM”), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians’ available time. XS L ...

Core Viewpoint - Fangzhou Inc. has entered a strategic partnership with Innovent Biologics to integrate AI-driven digital health services with innovative therapies for metabolic diseases and weight management, aiming to enhance patient outcomes in chronic disease care [1][2][4]. Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [10]. - Innovent Biologics specializes in developing and commercializing innovative therapies across various medical fields, including oncology, cardiovascular, and metabolic diseases [9]. Partnership Details - The partnership will combine Fangzhou's AI-enabled "H2H" digital healthcare ecosystem with Innovent's pipeline of novel therapies for diabetes and obesity, creating a new model that integrates AI technology with personalized services [2][4]. - The initial focus of the collaboration will be on diabetes and obesity, utilizing Fangzhou's "XS Core" AI large language model to power five key products aimed at delivering personalized digital care [4][6]. Market Context - China's weight management market is rapidly growing, with JPMorgan estimating that the market for weight management drugs could reach USD 14.9 billion by 2030 [2]. - The Chinese government has prioritized weight management as a public health issue, launching a three-year "Weight Management Year" campaign in 2024 [3]. Product Highlights - Innovent's Mazdutide therapy has shown significant weight reduction and improvements in health markers such as blood pressure and lipids, and it has been recognized as one of the "Top 10 Most Anticipated Medicines" globally for 2025 [5]. Future Plans - The companies plan to deepen their collaboration in AI-powered health management, aiming to expand access to innovative therapies and improve the quality and efficiency of chronic disease care in China [8].

SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to integrate digital health services with innovative therapies in metabolic diseases and weight management. Fangzhou’s founder, chairman and CEO Dr. Xie Fangmin and Innovent Biologics Vice President of Retail Tan Zaiqiang attended the signing ceremony. Fangzhou signed a strategic partnership with Inno ...